Xuehong Gui
Research Subjects
Xuehong Gui has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Guojuan Wang
Oncology Department, Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, China
1 shared publication - Hongbing Zhang
Department of Biochemistry and Molecular Biology, University of Kansas Medical Center, Kansas City, KS 66160, USA
1 shared publication - James P. Calvet
Department of Biochemistry and Molecular Biology, University of Kansas Medical Center, Kansas City, USA
1 shared publication - Julie Xia Zhou
Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
1 shared publication - Linda Xiaoyan Li
Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
1 shared publication - Wenyan Yu
Research Center for Differentiation and Development of TCM Basic Theory, Jiangxi Key Laboratory of Etiology and Biology of TCM, Discipline of Chinese and Western Integrative Medicine, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, P. R. China
1 shared publication
Latest Publications
- 2 November 2022
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 32 (7) , 1114-1126
Transcription factor FoxM1 promotes cyst growth in PKD1 mutant ADPKD
Autosomal dominant polycystic kidney disease (ADPKD) is driven by mutations in the PKD1 and PKD2 genes, and it is characterized by renal cyst formation, inflammation and fibrosis. Forkhead box protein M1 (FoxM1), a transcription factor of the Forkhead box (Fox) protein super family, has been reported to promote tumor formation, inflammation and fibrosis in many organs. However, the role and mechanism of FoxM1 in regulation of ADPKD progression is still poorly understood. Here, we show that FoxM1 is an important regulator of cyst growth in ADPKD. FoxM1 is upregulated in cyst-lining epithelial cells in Pkd1 mutant mouse kidneys and human ADPKD kidneys. FoxM1 promotes cystic renal epithelial cell proliferation by increasing the expression of Akt and Stat3 and the activation of ERK and Rb. FoxM1 also regulates cystic renal epithelial cell apoptosis through NF-κB signaling pathways. In addition, FoxM1 regulates the recruitment and retention of macrophages in Pkd1 mutant mouse kidneys, a process that is associated with FoxM1-mediated upregulation of monocyte chemotactic protein 1. Targeting FoxM1 with its specific inhibitor, FDI-6, delays cyst growth in rapidly progressing and slowly progressing Pkd1 mutant mouse kidneys. This study suggests that FoxM1 is a central and upstream regulator of ADPKD pathogenesis and provides a rationale for targeting FoxM1 as a therapeutic strategy for ADPKD treatment.
- 2 November 2022
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 32 (7) , 1114-1126
Transcription factor FoxM1 promotes cyst growth in PKD1 mutant ADPKD
Autosomal dominant polycystic kidney disease (ADPKD) is driven by mutations in the PKD1 and PKD2 genes, and it is characterized by renal cyst formation, inflammation and fibrosis. Forkhead box protein M1 (FoxM1), a transcription factor of the Forkhead box (Fox) protein super family, has been reported to promote tumor formation, inflammation and fibrosis in many organs. However, the role and mechanism of FoxM1 in regulation of ADPKD progression is still poorly understood. Here, we show that FoxM1 is an important regulator of cyst growth in ADPKD. FoxM1 is upregulated in cyst-lining epithelial cells in Pkd1 mutant mouse kidneys and human ADPKD kidneys. FoxM1 promotes cystic renal epithelial cell proliferation by increasing the expression of Akt and Stat3 and the activation of ERK and Rb. FoxM1 also regulates cystic renal epithelial cell apoptosis through NF-κB signaling pathways. In addition, FoxM1 regulates the recruitment and retention of macrophages in Pkd1 mutant mouse kidneys, a process that is associated with FoxM1-mediated upregulation of monocyte chemotactic protein 1. Targeting FoxM1 with its specific inhibitor, FDI-6, delays cyst growth in rapidly progressing and slowly progressing Pkd1 mutant mouse kidneys. This study suggests that FoxM1 is a central and upstream regulator of ADPKD pathogenesis and provides a rationale for targeting FoxM1 as a therapeutic strategy for ADPKD treatment.